BRAF and neoplasm: PFS was significantly lower among patients whose tumours carried mutations in BRAF (2.0 vs 3.9 months, HR 3.6, 95% CI 1.8–7.4), PIK3CA (2.5 vs 3.9 months, HR 2.1, 95% CI 1.2–3.9) or any of the three genes (2.5 vs 6.4 months, HR 2.1, 95% CI 1.3–3.2), and marginally lower in patients with KRAS-mutant tumours (2.5 vs 4.8 months, HR 1.5, 95% CI 0.9–2.3), compared with patients whose primary tumors were wild type at each locus (Figure 3, Supplementary Table 3).